|By Business Wire||
|March 3, 2014 08:06 AM EST||
TapImmune Inc. (OTCQB:TPIVD) is pleased to report that analysis of the interim data from the first set of patients in a Phase I clinical trial show that each of the patients have raised specific T-cell immune responses against a set of naturally processed HER2/neu Class II antigenic epitopes. The Phase I trial is being carried at the Mayo Clinic, Rochester, MN.
Importantly, this immune response data supports our contention that immune responses to our proprietary Class II antigens should be found in up to 84% of the patient population, making this potentially applicable to a much wider spectrum of patients when compared to other HER2/neu therapies; for example, Roche’s Herceptin®. Herceptin, a $6+B per year drug (2013) and the current standard of care for this patient population treats less than 20% of the HER2/neu+ breast cancer patient population, leaving a very large market opportunity for a TapImmune vaccine approach.
Glynn Wilson, TapImmune CEO said, “This is the second positive endpoint in the on-going study and when taken together, the promising data currently presented along with the earlier reported interim safety analysis are tremendously encouraging and provides a clear scientific rationale for progressing to a Phase II Clinical Study.” Moreover, Dr. Wilson stated that “The success in the current Clinical Trial supports the Company’s three pronged therapeutic approach augmenting the ability of Class I killer T-cells to kill by enhancing the biological activity of relevant Class II T-helper cells along with augmenting the fundamentals of antigen presentation, making this one of the most comprehensive therapeutic vaccines in clinical development. ”
Dr. Keith Knutson, Director Cancer Vaccines and Immune Therapies Program, Vaccine & Gene Therapy Institute of Florida, this trial’s Principal Investigator, further commented that “The finding of specific immune responses in all patients has confirmed expectations that our approach is well reasoned, capable of reaching a broad population of breast cancer patients and is amenable to other HER2/neu indications such as colorectal and ovarian cancers. We are extremely pleased with the results thus far and expect to advance these studies to a Phase II Clinical Study in the near future.”
Earlier the company had reported that the first endpoint to demonstrate safety on these patients was met.
In the current analysis of the first six patients, immune responses were stimulated against the HER2/neu antigens corresponding to T-cell epitopes mapping directly to both external and internal domains of the HER2/neu protein. Five patients showed immune responses against all four epitopes while one patient had immune responses to 3 epitopes. The use of these epitopes, discovered by Dr. Keith Knutson as naturally processed subdominant epitopes from breast cancer patient samples, illustrates an important focus of our vaccine development strategy, namely, to identify and amplify naturally occurring patient immune responses to cancer antigens.
Ultimately, TapImmune’s therapeutic approach is designed to stimulate a long-lived Killer T-cell (CD8+, Class 1 HLA) mediated immune response resulting from the concomitant stimulation of one or more Helper T-Cell (CD4+ Class 2 HLA) responses. In contrast, Herceptin®, a monoclonal antibody directed to an external domain only of the HER2/neu protein, is not designed or intended to stimulate a Killer T-cell response. Furthermore, we believe that the use of TapImmune’s candidate HER2/neu vaccine composition(s) could be expanded to include indications where there is a large market opportunity and unmet need, such as ovarian and colorectal cancers.
TapImmune is sponsoring this Phase I study and has an Exclusive Option to License the antigen technology at the end of Phase I. These studies are being conducted in breast cancer patients who have finished standard Herceptin®-based therapy and are at a high risk of disease recurrence.
About TapImmune Inc.
TapImmune Inc. is an immunotherapy company specializing in the development of innovative vaccine technologies for the treatment of cancer and infectious disease. The Company’s vaccine compositions, peptide or nucleic acid-based, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patients’ killer T-cells, helper T-cells and to restore or further augment antigen presentation by the modulation of TAP (Transporter associated with Antigen Processing). The Company believes that its vaccine compositions may be used as stand-alone medications or in combination with current treatment modalities. Please visit the Company’s website at www.tapimmune.com for details.
Forward-Looking Statement Disclaimer: This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements”. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements
@ThingsExpo has been named the Most Influential ‘Smart Cities - IIoT' Account and @BigDataExpo has been named fourteenth by Right Relevance (RR), which provides curated information and intelligence on approximately 50,000 topics. In addition, Right Relevance provides an Insights offering that combines the above Topics and Influencers information with real time conversations to provide actionable intelligence with visualizations to enable decision making. The Insights service is applicable to eve...
Apr. 27, 2017 06:30 PM EDT Reads: 2,813
Building a cross-cloud operational model can be a daunting task. Per-cloud silos are not the answer, but neither is a fully generic abstraction plane that strips out capabilities unique to a particular provider. In his session at 20th Cloud Expo, Chris Wolf, VP & Chief Technology Officer, Global Field & Industry at VMware, will discuss how successful organizations approach cloud operations and management, with insights into where operations should be centralized and when it’s best to decentraliz...
Apr. 27, 2017 06:00 PM EDT Reads: 778
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm.
Apr. 27, 2017 06:00 PM EDT Reads: 1,026
Cybersecurity is a critical component of software development in many industries including medical devices. However, code is not always written to be robust or secure from the unknown or the unexpected. This gap can make medical devices susceptible to cybersecurity attacks ranging from compromised personal health information to life-sustaining treatment. In his session at @ThingsExpo, Clark Fortney, Software Engineer at Battelle, will discuss how programming oversight using key methods can incre...
Apr. 27, 2017 05:30 PM EDT Reads: 3,952
The goal of Continuous Testing is to shift testing left to find defects earlier and release software faster. This can be achieved by integrating a set of open source functional and performance testing tools in the early stages of your software delivery lifecycle. There is one process that binds all application delivery stages together into one well-orchestrated machine: Continuous Testing. Continuous Testing is the conveyor belt between the Software Factory and production stages. Artifacts are ...
Apr. 27, 2017 05:15 PM EDT Reads: 1,265
In recent years, containers have taken the world by storm. Companies of all sizes and industries have realized the massive benefits of containers, such as unprecedented mobility, higher hardware utilization, and increased flexibility and agility; however, many containers today are non-persistent. Containers without persistence miss out on many benefits, and in many cases simply pass the responsibility of persistence onto other infrastructure, adding additional complexity.
Apr. 27, 2017 04:30 PM EDT Reads: 2,287
Quickly find the root cause of complex database problems slowing down your applications. Up to 88% of all application performance issues are related to the database. DPA’s unique response time analysis shows you exactly what needs fixing - in four clicks or less. Optimize performance anywhere. Database Performance Analyzer monitors on-premises, on VMware®, and in the Cloud, including Amazon® AWS and Azure™ virtual machines.
Apr. 27, 2017 04:15 PM EDT Reads: 1,965
Most technology leaders, contemporary and from the hardware era, are reshaping their businesses to do software in the hope of capturing value in IoT. Although IoT is relatively new in the market, it has already gone through many promotional terms such as IoE, IoX, SDX, Edge/Fog, Mist Compute, etc. Ultimately, irrespective of the name, it is about deriving value from independent software assets participating in an ecosystem as one comprehensive solution.
Apr. 27, 2017 03:45 PM EDT Reads: 555
SYS-CON Events announced today that Progress, a global leader in application development, has been named “Bronze Sponsor” of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Enterprises today are rapidly adopting the cloud, while continuing to retain business-critical/sensitive data inside the firewall. This is creating two separate data silos – one inside the firewall and the other outside the firewall. Cloud ISVs oft...
Apr. 27, 2017 03:28 PM EDT Reads: 256
Developers want to create better apps faster. Static clouds are giving way to scalable systems, with dynamic resource allocation and application monitoring. You won't hear that chant from users on any picket line, but helping developers to create better apps faster is the mission of Lee Atchison, principal cloud architect and advocate at New Relic Inc., based in San Francisco. His singular job is to understand and drive the industry in the areas of cloud architecture, microservices, scalability ...
Apr. 27, 2017 03:00 PM EDT Reads: 3,572
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, New York, and 21st International Cloud Expo, which will take place in November in Silicon Valley, California.
Apr. 27, 2017 02:00 PM EDT Reads: 2,427
The 20th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held June 6-8, 2017, at the Javits Center in New York City, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Containers, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportunity. Submit your speaking proposal ...
Apr. 27, 2017 01:45 PM EDT Reads: 1,299
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In his Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, will explore t...
Apr. 27, 2017 01:30 PM EDT Reads: 790
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists will examine how DevOps helps to meet th...
Apr. 27, 2017 01:15 PM EDT Reads: 1,590
SYS-CON Events announced today that Juniper Networks (NYSE: JNPR), an industry leader in automated, scalable and secure networks, will exhibit at SYS-CON's 20th International Cloud Expo®, which will take place on June 6-8, 2017, at the Javits Center in New York City, NY. Juniper Networks challenges the status quo with products, solutions and services that transform the economics of networking. The company co-innovates with customers and partners to deliver automated, scalable and secure network...
Apr. 27, 2017 01:15 PM EDT Reads: 4,952